IndustryCompany release

Artivion third-quarter revenue rises 9% to $123.8M as full-year guidance is narrowed

🇺🇸 Artivion, Inc. (AORT) · Thu 05 Nov 2026

The aortic disease specialist posted a $7.9M net loss and lower adjusted EBITDA, while preparing a January 2027 US launch of NEXUS.

Artivion, a cardiac and vascular surgery company focused on aortic disease, reported third-quarter 2026 results on 5 November 2026. Revenue rose 9% to $123.8M, with growth led by its On-X heart valve products and stent grafts.

The company recorded a net loss of $7.9M for the quarter, and adjusted EBITDA was lower than in the comparable period. The summary provided does not give further detail on the drivers of the loss or the size of the EBITDA decline.

Artivion narrowed its 2026 revenue guidance to a range of $484M to $492M. It also said US implants of its AMDS device grew following the product's recent premarket approval (PMA) from the US regulator.

Looking ahead, the company is preparing for a US launch of NEXUS in January 2027. No further details on the product or the launch plan were available in the material reviewed.

What it means for your team

  • The recent US PMA for AMDS is already translating into commercial uptake, an example of approval-to-launch momentum in the aortic device segment.
  • Teams tracking Artivion should note the January 2027 NEXUS launch timeline when planning market-access, training and post-market surveillance activities.
  • Narrowed guidance of $484M-$492M gives a tighter view of expected 2026 performance, though profitability remains under pressure.

Company's press release (SEC filing): Artivion, Inc. ↗

Article written by VigiEye from the official source (Artivion, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →